{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T09:11:03Z","timestamp":1778490663354,"version":"3.51.4"},"reference-count":40,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The current study investigates the anorectic interaction and safety of the mazindol-metformin combination in rats. Isobologram and interaction index were used to determine anorectic interaction between mazindol and metformin in the sweetened milk model. The safety profile of the mazindol-metformin combination was determined by measuring anxiety, blood pressure, hematic biometry and blood chemistry. An acute dose of mazindol and metformin administered\n                    <jats:italic>per os<\/jats:italic>\n                    , individually or as a mixture, has reduced the milk consumption in rats in a dose-dependent manner. Theoretical effective dose 40 (\n                    <jats:italic>ED<\/jats:italic>\n                    <jats:sub>40t<\/jats:sub>\n                    ) did not differ from the experimental effective dose 40 (\n                    <jats:italic>ED<\/jats:italic>\n                    <jats:sub>40e<\/jats:sub>\n                    ) obtained with the mazindol-metformin mixture in the anorexia experiments, by Student\u2032s\n                    <jats:italic>t<\/jats:italic>\n                    -test. In addition, the interaction index confirmed the additive anorectic effect between both drugs. A single oral dose of\n                    <jats:italic>ED<\/jats:italic>\n                    <jats:sub>40e<\/jats:sub>\n                    mazindol-metformin mixture induced anxiolysis in the elevated plus-maze test. Moreover, oral administration of mazindol-metformin combination for 3 months significantly decreased glycemia, but not blood pressure nor other parameters of hematic biometry and blood chemistry. Results suggest that mazindol-metformin combination exerts an additive anorectic effect, as well as anxiolytic and hypoglycemic properties. Mazindol-metformin combination might be useful in obese patients with anxiety disorders or diabetes risk factors.\n                  <\/jats:p>","DOI":"10.2478\/acph-2021-0019","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T21:17:57Z","timestamp":1611350277000},"page":"279-291","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of the metformin-mazindol anorectic combination in rat"],"prefix":"10.2478","volume":"71","author":[{"given":"Federico","family":"Arg\u00fcelles-Tello","sequence":"first","affiliation":[{"name":"Secci\u00f3n de Estudios de Posgrado e Investigaci\u00f3n, Escuela Superior de Medicina , Instituto Polit\u00e9cnico Nacional Plan de San Luis y D\u00edaz Mir\u00f3n s\/n Col. Casco de Santo Tomas , Miguel Hidalgo, 11340, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Eduardo","family":"Roa-Coria","sequence":"additional","affiliation":[{"name":"Secci\u00f3n de Estudios de Posgrado e Investigaci\u00f3n, Escuela Superior de Medicina , Instituto Polit\u00e9cnico Nacional Plan de San Luis y D\u00edaz Mir\u00f3n s\/n Col. Casco de Santo Tomas , Miguel Hidalgo, 11340, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel","family":"Z\u00fa\u00f1iga-Romero","sequence":"additional","affiliation":[{"name":"Secci\u00f3n de Estudios de Posgrado e Investigaci\u00f3n, Escuela Superior de Medicina , Instituto Polit\u00e9cnico Nacional Plan de San Luis y D\u00edaz Mir\u00f3n s\/n Col. Casco de Santo Tomas , Miguel Hidalgo, 11340, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Huerta-Cruz","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n en Farmacolog\u00eda Instituto Nacional de Enfermedades Respiratorias , Ismael Cosio Villegas Secretar\u00eda de Salud, Calzada de Tlalpan 4502, Col. Belisario Dom\u00ednguez Secci\u00f3n XVI, Tlalpan, 14080, Ciudad de M\u00e9xico M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geovanna Nalley","family":"Qui\u00f1onez-Bastidas","sequence":"additional","affiliation":[{"name":"Secci\u00f3n de Estudios de Posgrado e Investigaci\u00f3n, Escuela Superior de Medicina , Instituto Polit\u00e9cnico Nacional Plan de San Luis y D\u00edaz Mir\u00f3n s\/n Col. Casco de Santo Tomas , Miguel Hidalgo, 11340, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Javier","family":"Flores-Murrieta","sequence":"additional","affiliation":[{"name":"Secci\u00f3n de Estudios de Posgrado e Investigaci\u00f3n, Escuela Superior de Medicina , Instituto Polit\u00e9cnico Nacional Plan de San Luis y D\u00edaz Mir\u00f3n s\/n Col. Casco de Santo Tomas , Miguel Hidalgo, 11340, Ciudad de M\u00e9xico, M\u00e9xico"},{"name":"Unidad de Investigaci\u00f3n en Farmacolog\u00eda Instituto Nacional de Enfermedades Respiratorias , Ismael Cosio Villegas Secretar\u00eda de Salud, Calzada de Tlalpan 4502, Col. Belisario Dom\u00ednguez Secci\u00f3n XVI, Tlalpan, 14080, Ciudad de M\u00e9xico M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9ctor Isaac","family":"Rocha-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Secci\u00f3n de Estudios de Posgrado e Investigaci\u00f3n, Escuela Superior de Medicina , Instituto Polit\u00e9cnico Nacional Plan de San Luis y D\u00edaz Mir\u00f3n s\/n Col. Casco de Santo Tomas , Miguel Hidalgo, 11340, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Gerardo","family":"Reyes-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Secci\u00f3n de Estudios de Posgrado e Investigaci\u00f3n, Escuela Superior de Medicina , Instituto Polit\u00e9cnico Nacional Plan de San Luis y D\u00edaz Mir\u00f3n s\/n Col. Casco de Santo Tomas , Miguel Hidalgo, 11340, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2020,11,4]]},"reference":[{"key":"2026051108205517897_j_acph-2021-0019_ref_001_w2aab3b7c17b1b6b1ab1ab1Aa","doi-asserted-by":"crossref","unstructured":"1. W. T. Cefalu, G. A. Bray, P. D. Home, W. T. Garvey, S. Klein, F. X. Pi-Sunyer, F. B. Hu, I. Raz, L. Van Gaal, B. M. Wolfe and D. H. Ryan, Advances in the science, treatment, and prevention of the disease of obesity: Reflections from a diabetes care editors\u2019 expert forum, Diabetes Care38 (2015) 1567\u20131582; https:\/\/doi.org\/10.2337\/dc15-108110.2337\/dc15-1081","DOI":"10.2337\/dc15-1081"},{"key":"2026051108205517897_j_acph-2021-0019_ref_002_w2aab3b7c17b1b6b1ab1ab2Aa","doi-asserted-by":"crossref","unstructured":"2. Global BMI Mortality Collaboration, E. Di Angelantonio, S. Bhupathiraju, D. Wormser, P. Gao, S. Kaptoge, A. Berrington de Gonzalez, B. J. Cairns, R. Huxley, Ch. L. Jackson, G. Joshy, S. Lewington, J. E. Manson, N. Murphy, A. V. Patel, J. M. Samet, M. Woodward, W. Zheng, M. Zhou, N. Bansal, A. Barricarte, B. Carter, J. R. Cerhan, G. D. Smith, X. Fang, O. H. Franco, J. Green, J. Halsey, J. S. Hildebrand, K. J. Jung, R. J. Korda, D. F. McLerran, S. C. Moore, L. M. O\u2019Keeffe, E. Paige, A. Ramond, G. K. Reeves, B. Rolland, C. Sacerdote, N. Sattar, E. Sofianopoulou, J. Stevens, M. Thun, H. Ueshima, L. Yang, Y. D. Yun, P. Willeit, E. Banks, V. Beral, Zh. Chen, S. M. Gapstur, M. J. Gunter, P. Hartge, S. H. Jee, T. H. Lam, R. Peto, J. D. Potter, W. C. Willett, S. G. Thompson, J. Danesh and F. B. Hu, Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents, Lancet388 (2016) 776\u2013786; https:\/\/doi.org\/10.1016\/S0140-6736(16)30175-110.1016\/S0140-6736(16)30175-1","DOI":"10.1016\/S0140-6736(16)30175-1"},{"key":"2026051108205517897_j_acph-2021-0019_ref_003_w2aab3b7c17b1b6b1ab1ab3Aa","doi-asserted-by":"crossref","unstructured":"3. F. L. Greenway, Physiological adaptations to weight loss and factors favouring weight regain, Int. J. Obes. (London) 39 (2015) 1188\u20131196; https:\/\/doi.org\/10.1038\/ijo.2015.5910.1038\/ijo.2015.59476692525896063","DOI":"10.1038\/ijo.2015.59"},{"key":"2026051108205517897_j_acph-2021-0019_ref_004_w2aab3b7c17b1b6b1ab1ab4Aa","doi-asserted-by":"crossref","unstructured":"4. C. Langenberg, S. J. Sharp, P. W. Franks, R. A. Scott, P. Deloukas, N. G. Forouhi, P. Froguel, L. C. Groop, T. Hansen, L. Palla, O. Pedersen, M. B. Schulze, M. J. Tormo, E. Wheeler, C. Agnoli, L. Arriola, A. Barricarte, H. Boeing, G. M. Clarke, F. Clavel-Chapelon, E. J. Duell, G. Fagherazzi, R. Kaaks, N. D. Kerrison, T. J. Key, K. T. Khaw, J. Kr\u00f6ger, M. Lajous, A. P. Morris, C. Navarro, P. M. Nilsson, K. Overvad, D. Palli, S. Panico, J. R. Quir\u00f3s, O. Rolandsson, C. Sacerdote, M. J. S\u00e1nchez, N. Slimani, A. M. Spijkerman, R. Tumino, D. L. van der A, Y. T. van der Schouw, I. Barroso, M. I. McCarthy, E. Riboli and N. J. Wareham, Gene-lifestyle interaction and type 2 diabetes: the EPIC interact case-cohort study, PLoS Med.11 (2014) e1001647; https:\/\/doi.org\/10.1371\/journal.pmed.100164710.1371\/journal.pmed.1001647402818324845081","DOI":"10.1371\/journal.pmed.1001647"},{"key":"2026051108205517897_j_acph-2021-0019_ref_005_w2aab3b7c17b1b6b1ab1ab5Aa","doi-asserted-by":"crossref","unstructured":"5. J. Jordan, A. Astrup, S. Engeli, K. Narkiewicz, W. W. Day and N. Finer, Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity, J. Hypertens.32 (2014) 1178\u20131188; https:\/\/doi.org\/10.1097\/HJH.000000000000014510.1097\/HJH.0000000000000145401156724621808","DOI":"10.1097\/HJH.0000000000000145"},{"key":"2026051108205517897_j_acph-2021-0019_ref_006_w2aab3b7c17b1b6b1ab1ab6Aa","doi-asserted-by":"crossref","unstructured":"6. S. K. Malin and S. R. Kashyap, Effects of metformin on weight loss: potential mechanisms, Curr. Opin. Endocrinol. Diabetes Obes.21 (2014) 323\u2013329; https:\/\/doi.org\/10.1097\/MED.000000000000009510.1097\/MED.000000000000009525105996","DOI":"10.1097\/MED.0000000000000095"},{"key":"2026051108205517897_j_acph-2021-0019_ref_007_w2aab3b7c17b1b6b1ab1ab7Aa","doi-asserted-by":"crossref","unstructured":"7. G. Aubert, V. Mansuy, M. J. Voirol, L. Pellerin and F. P. Pralong, The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression, Metabolism60 (2011) 327\u2013334; https:\/\/doi.org\/10.1016\/j.metabol.2010.02.00710.1016\/j.metabol.2010.02.00720303124","DOI":"10.1016\/j.metabol.2010.02.007"},{"key":"2026051108205517897_j_acph-2021-0019_ref_008_w2aab3b7c17b1b6b1ab1ab8Aa","doi-asserted-by":"crossref","unstructured":"8. J. R. Lindsay, N. A. Duffy, A. M. McKillop, J. Ardill, F. P. O\u2019Harte, P. R. Flatt and P. M. Bell, Inhibition of dipeptidyl peptidase IV activity by oral metformin in type 2 diabetes, Diabet. Med.22 (2005) 654\u2013657; https:\/\/doi.org\/10.1111\/j.1464-5491.2005.01461.x10.1111\/j.1464-5491.2005.01461.x15842525","DOI":"10.1111\/j.1464-5491.2005.01461.x"},{"key":"2026051108205517897_j_acph-2021-0019_ref_009_w2aab3b7c17b1b6b1ab1ab9Aa","doi-asserted-by":"crossref","unstructured":"9. A. J. Mulherin, A. H. Oh, H. Kim, A. Grieco, L. M. Lauffer and P. L. Brubaker, Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell, Endocrinology152 (2011) 4610\u20134619; https:\/\/doi.org\/10.1210\/en.2011-148510.1210\/en.2011-148521971158","DOI":"10.1210\/en.2011-1485"},{"key":"2026051108205517897_j_acph-2021-0019_ref_010_w2aab3b7c17b1b6b1ab1ac10Aa","doi-asserted-by":"crossref","unstructured":"10. W. C. Knowler, E. Barrett-Connor, S. E. Fowler, R. F. Hamman, J. M. Lachin, E. A. Walker and D. M. Nathan, Diabetes Prevention Program Research Group, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N. Engl. J. Med.346 (2002) 393\u2013403; https:\/\/doi.org\/10.1056\/NEJMoa01251210.1056\/NEJMoa012512137092611832527","DOI":"10.1056\/NEJMoa012512"},{"key":"2026051108205517897_j_acph-2021-0019_ref_011_w2aab3b7c17b1b6b1ab1ac11Aa","doi-asserted-by":"crossref","unstructured":"11. S. Inoue, M. Egawa, S. Satoh, M. Saito, H. Suzuki, Y. Kumahara, M. Abe, A. Kumagai, Y. Goto and K. Shizume, Clinical and basic aspects of an anorexiant, mazindol, as an antiobesity agent in Japan, Am. J. Clin. Nutr.55 (1992) 199S\u2013202S; https:\/\/doi.org\/10.1093\/ajcn\/55.1.199s10.1093\/ajcn\/55.1.199s","DOI":"10.1093\/ajcn\/55.1.199s"},{"key":"2026051108205517897_j_acph-2021-0019_ref_012_w2aab3b7c17b1b6b1ab1ac12Aa","doi-asserted-by":"crossref","unstructured":"12. T. Shiraishi, Mazindol effects on the salivary and gastric acid secretory mechanisms, Nihon Yakurigaku Zasshi (Folia Pharmacol.) 83 (1984) 159\u2013172; https:\/\/doi.org\/10.1254\/fpj.83.15910.1254\/fpj.83.159","DOI":"10.1254\/fpj.83.159"},{"key":"2026051108205517897_j_acph-2021-0019_ref_013_w2aab3b7c17b1b6b1ab1ac13Aa","unstructured":"13. G. Slama, A. Selmi, M. Hautecouverture and G. Tchobroutsky, Double blind clinical trial of mazindol on weight loss blood glucose, plasma insulin and serum lipids in overweight diabetic patients, Diabet. Metab.4 (1978) 193\u2013199."},{"key":"2026051108205517897_j_acph-2021-0019_ref_014_w2aab3b7c17b1b6b1ab1ac14Aa","doi-asserted-by":"crossref","unstructured":"14. M. Usami, Y. Seino, S. Nishi, H. Nakahara, M. Ikeda, S. Matsukura and H. Imura, Effect of mazindol on insulin and glucagon secretion in ventromedial hypothalamic obese rats, Nihon Yakurigaku Zasshi (Folia Pharmacol.) 85 (1985) 297\u2013303; https:\/\/doi.org\/10.1254\/fpj.85.29710.1254\/fpj.85.297","DOI":"10.1254\/fpj.85.297"},{"key":"2026051108205517897_j_acph-2021-0019_ref_015_w2aab3b7c17b1b6b1ab1ac15Aa","doi-asserted-by":"crossref","unstructured":"15. L. E. Cruz-\u00c1lvarez, A. Z\u00fa\u00f1iga-Romero, J. C. Huerta-Cruz, F. J. Flores-Murrieta, J. G. Reyes-Garc\u00eda, C. I. Araiza-Salda\u00f1a and H. I. Rocha-Gonz\u00e1lez, Antiallodynic interaction and motor performance of the pregabalin\/thioctic acid and pregabalin\/\u03b1-tocopherol combinations in neonatal streptozotocin-induced diabetic rats, Drug Dev. Res. 79 (2018) 362\u2013369; https:\/\/doi.org\/10.1002\/ddr.2147310.1002\/ddr.21473","DOI":"10.1002\/ddr.21473"},{"key":"2026051108205517897_j_acph-2021-0019_ref_016_w2aab3b7c17b1b6b1ab1ac16Aa","doi-asserted-by":"crossref","unstructured":"16. S. Pellow, P. Chopin, S. E. File and M. Briley, Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat, J. Neurosci. Meth.14 (1985) 149\u2013167; https:\/\/doi.org\/10.1016\/0165-0270(85)90031-710.1016\/0165-0270(85)90031-7","DOI":"10.1016\/0165-0270(85)90031-7"},{"key":"2026051108205517897_j_acph-2021-0019_ref_017_w2aab3b7c17b1b6b1ab1ac17Aa","doi-asserted-by":"crossref","unstructured":"17. R. J. Tallarida, Drug Synergism and Dose-Effect Data Analysis, Chapman & Hall\/CRC, New York 2000, pp. 1\u2013264.10.1201\/9781420036107","DOI":"10.1201\/9781420036107"},{"key":"2026051108205517897_j_acph-2021-0019_ref_018_w2aab3b7c17b1b6b1ab1ac18Aa","doi-asserted-by":"crossref","unstructured":"18. R. J. Tallarida, The interaction index: a measure of drug synergism, Pain98 (2002) 163\u2013168; https:\/\/doi.org\/10.1016\/S0304-3959(02)00041-610.1016\/S0304-3959(02)00041-6","DOI":"10.1016\/S0304-3959(02)00041-6"},{"key":"2026051108205517897_j_acph-2021-0019_ref_019_w2aab3b7c17b1b6b1ab1ac19Aa","doi-asserted-by":"crossref","unstructured":"19. T. Yoshida, T. Umekawa, Y. Wakabayashi, K. Yoshimoto, N. Sakane and M. Kondo, Anti-obesity and anti-diabetic effects of mazindol in yellow KK mice: its activating effect on brown adipose tissue thermogenesis, Clin. Exp. Pharmacol. Physiol.23 (1996) 476\u2013482; https:\/\/doi.org\/10.1111\/j.1440-1681.1996.tb02764.x10.1111\/j.1440-1681.1996.tb02764.x","DOI":"10.1111\/j.1440-1681.1996.tb02764.x"},{"key":"2026051108205517897_j_acph-2021-0019_ref_020_w2aab3b7c17b1b6b1ab1ac20Aa","doi-asserted-by":"crossref","unstructured":"20. R. C. Lucchetta, B. S. Riveros, R. Pontarolo, R. B. Radominski, M. F. Otuki, F. Fernandez-Llimos and C. J. Correr, Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients, Clinics (Sao Paulo) 72 (2017) 317\u2013324; https:\/\/doi.org\/10.6061\/clinics\/2017(05)1010.6061\/clinics\/2017(05)10","DOI":"10.6061\/clinics\/2017(05)10"},{"key":"2026051108205517897_j_acph-2021-0019_ref_021_w2aab3b7c17b1b6b1ab1ac21Aa","doi-asserted-by":"crossref","unstructured":"21. J. Rouru, R. Huupponen, U. Pesonen and M. Koulu, Subchronic treatment with metformin produces anorectic effect and reduces hyperinsulinemia in genetically obese Zucker rats, Life Sci.50 (1992) 1813\u20131820; https:\/\/doi.org\/10.1016\/0024-3205(92)90066-X10.1016\/0024-3205(92)90066-X","DOI":"10.1016\/0024-3205(92)90066-X"},{"key":"2026051108205517897_j_acph-2021-0019_ref_022_w2aab3b7c17b1b6b1ab1ac22Aa","doi-asserted-by":"crossref","unstructured":"22. K. N. de Oliveira Santana, D. F. Lelis, K. L. Mendes, J. F. Lula, A. F. Para\u00edso, J. M. Andrade, J. D. Feltenberger, J. Cota, D. V. da Costa, A. M. de Paula, A. L. Guimar\u00e3es and S. H. Santos, Metformin reduces lipogenesis markers in obese mice fed a low-carbohydrate and high-fat diet, Lipids51 (2016) 1375\u20131384; https:\/\/doi.org\/10.1007\/s11745-016-4209-y10.1007\/s11745-016-4209-y","DOI":"10.1007\/s11745-016-4209-y"},{"key":"2026051108205517897_j_acph-2021-0019_ref_023_w2aab3b7c17b1b6b1ab1ac23Aa","doi-asserted-by":"crossref","unstructured":"23. C. M. Ashwell and J. P. McMurtry, Hypoglycemia and reduced feed intake in broiler chickens treated with metformin, Poult. Sci.82 (2003) 106\u2013110; https:\/\/doi.org\/106-110.10.1093\/ps\/82.1.10610.1093\/ps\/82.1.106","DOI":"10.1093\/ps\/82.1.106"},{"key":"2026051108205517897_j_acph-2021-0019_ref_024_w2aab3b7c17b1b6b1ab1ac24Aa","doi-asserted-by":"crossref","unstructured":"24. A. Saenz, I. Fernandez-Esteban, A. Mataix, M. Ausejo, M. Roque and D. Moher, Metformin mono-therapy for type 2 diabetes mellitus, Cochrane Database Syst. Rev.3 (2005) CD002966; https:\/\/doi.org\/10.1002\/14651858.CD002966.pub310.1002\/14651858.CD002966.pub3","DOI":"10.1002\/14651858.CD002966.pub3"},{"key":"2026051108205517897_j_acph-2021-0019_ref_025_w2aab3b7c17b1b6b1ab1ac25Aa","doi-asserted-by":"crossref","unstructured":"25. S. K. Graff, F. M. Mario, P. Ziegelmann and P. M. Spritzer, Effects of orlistat vs. metformin on weight loss-related clinical variables in women with PCOS: systematic review and meta-analysis, Int. J. Clin. Pract.70 (2016) 450\u2013461; https:\/\/doi.org\/10.1111\/ijcp.1278710.1111\/ijcp.12787","DOI":"10.1111\/ijcp.12787"},{"key":"2026051108205517897_j_acph-2021-0019_ref_026_w2aab3b7c17b1b6b1ab1ac26Aa","doi-asserted-by":"crossref","unstructured":"26. F. Hui, Y. Zhang, T. Ren, X. Li, M. Zhao and Q. Zhao, Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis, Eur. J. Clin. Pharmacol.75 (2019) 437\u2013450; https:\/\/doi.org\/10.1007\/s00228-018-2593-310.1007\/s00228-018-2593-3","DOI":"10.1007\/s00228-018-2593-3"},{"key":"2026051108205517897_j_acph-2021-0019_ref_027_w2aab3b7c17b1b6b1ab1ac27Aa","doi-asserted-by":"crossref","unstructured":"27. L. C. Iorio, E. A. Ryan and J. H. Gogerty, Combinations of selected CNS depressants with d-amphetamine or mazindol on food intake and motor activity of rats, Eur. J. Pharmacol.36 (1976) 89\u201394; https:\/\/doi.org\/10.1016\/0014-2999(76)90260-010.1016\/0014-2999(76)90260-0","DOI":"10.1016\/0014-2999(76)90260-0"},{"key":"2026051108205517897_j_acph-2021-0019_ref_028_w2aab3b7c17b1b6b1ab1ac28Aa","doi-asserted-by":"crossref","unstructured":"28. Z. L. Kruk and M. R. Zarrindast, Mazindol anorexia is mediated by activation of dopaminergic mechanisms, Br. J. Pharmacol.58 (1976) 367\u2013372; https:\/\/doi.org\/10.1111\/j.1476-5381.1976.tb07713.x10.1111\/j.1476-5381.1976.tb07713.x","DOI":"10.1111\/j.1476-5381.1976.tb07713.x"},{"key":"2026051108205517897_j_acph-2021-0019_ref_029_w2aab3b7c17b1b6b1ab1ac29Aa","doi-asserted-by":"crossref","unstructured":"29. N. Shimizu, S. Take, T. Hori and Y. Oomura, Hypothalamic microdialysis of mazindol causes anorexia with increase in synaptic serotonin in rats, Physiol. Behav.49 (1991) 131\u2013134; https:\/\/doi.org\/10.1016\/0031-9384(91)90243-H10.1016\/0031-9384(91)90243-H","DOI":"10.1016\/0031-9384(91)90243-H"},{"key":"2026051108205517897_j_acph-2021-0019_ref_030_w2aab3b7c17b1b6b1ab1ac30Aa","unstructured":"30. R. G. Engstrom, L. A. Kelly and J. H. Gogerty, The effects of 5-hydroxy-5(4\u2019-chlorophenyl)-2,3-di-hydro-5H-imidazo(2,1-a)isoindole(mazindol, SaH 42-548) on the metabolism of brain norepinephrine, Arch. Int. Pharmacodyn. Ther.214 (1975) 308\u2013321."},{"key":"2026051108205517897_j_acph-2021-0019_ref_031_w2aab3b7c17b1b6b1ab1ac31Aa","doi-asserted-by":"crossref","unstructured":"31. S. K. Sikdar, Y. Oomura and A. Inokuchi, Effects of mazindol on rat lateral hypothalamic neurons, Brain Res. Bull.15 (1985) 33\u201338; https:\/\/doi.org\/10.1016\/0361-9230(85)90058-910.1016\/0361-9230(85)90058-9","DOI":"10.1016\/0361-9230(85)90058-9"},{"key":"2026051108205517897_j_acph-2021-0019_ref_032_w2aab3b7c17b1b6b1ab1ac32Aa","unstructured":"32. S. Inoue, M. Tsuchiya and Y. Takamura, Effects of mazindol on food intake in ventromedial hypothalamic lesioned rats and glucose absorption in rats, Int. J. Obes.11 (1987) 63\u201369."},{"key":"2026051108205517897_j_acph-2021-0019_ref_033_w2aab3b7c17b1b6b1ab1ac33Aa","doi-asserted-by":"crossref","unstructured":"33. M. J. Kirby and P. Turner, Do \u201eanorectic\u201d drugs produce weight loss by appetite suppression? Lancet1 (1976) 566\u2013567; https:\/\/doi.org\/10.1016\/S0140-6736(76)90360-310.1016\/S0140-6736(76)90360-3","DOI":"10.1016\/S0140-6736(76)90360-3"},{"key":"2026051108205517897_j_acph-2021-0019_ref_034_w2aab3b7c17b1b6b1ab1ac34Aa","doi-asserted-by":"crossref","unstructured":"34. D. Stevanovic, K. Janjetovic, M. Misirkic, L. Vucicevic, M. Sumarac-Dumanovic, D. Micic, V. Starcevic and V. Trajkovic, Intracerebroventricular administration of metformin inhibits ghrelin-induced hypothalamic AMP-kinase signalling and food intake, Neuroendocrinology96 (2012) 24\u201331; https:\/\/doi.org\/10.1159\/00033396310.1159\/000333963","DOI":"10.1159\/000333963"},{"key":"2026051108205517897_j_acph-2021-0019_ref_035_w2aab3b7c17b1b6b1ab1ac35Aa","doi-asserted-by":"crossref","unstructured":"35. W. S. Lv, J. P. Wen, L. Li, R. X. Sun, J. Wang, Y. X. Xian, C. X. Cao, Y. L. Wang and Y. Y. Gao, The effect of metformin on food intake and its potential role in hypothalamic regulation in obese diabetic rats, Brain Res.1444 (2012) 11\u201319; https:\/\/doi.org\/10.1016\/j.brainres.2012.01.02810.1016\/j.brainres.2012.01.028","DOI":"10.1016\/j.brainres.2012.01.028"},{"key":"2026051108205517897_j_acph-2021-0019_ref_036_w2aab3b7c17b1b6b1ab1ac36Aa","doi-asserted-by":"crossref","unstructured":"36. R. J. Rodgers and A. Dalvi, Anxiety, defence and the elevated plus-maze, Neurosci. Biobehav. Rev.21 (1997) 801\u2013810; https:\/\/doi.org\/10.1016\/S0149-7634(96)00058-910.1016\/S0149-7634(96)00058-9","DOI":"10.1016\/S0149-7634(96)00058-9"},{"key":"2026051108205517897_j_acph-2021-0019_ref_037_w2aab3b7c17b1b6b1ab1ac37Aa","unstructured":"37. R. Mattei and E. A. Carlini, Mazindol: anorectic and behavioral effects in female rats, Arch. Int. Pharmacodyn. Ther.330 (1995) 279\u2013287."},{"key":"2026051108205517897_j_acph-2021-0019_ref_038_w2aab3b7c17b1b6b1ab1ac38Aa","doi-asserted-by":"crossref","unstructured":"38. G. Gariepy, D. Nitka and N. Schmitz, The association between obesity and anxiety disorders in the population: a systematic review and meta-analysis, Int. J. Obes. (London) 34 (2010) 407\u2013419; https:\/\/doi.org\/10.1038\/ijo.2009.25210.1038\/ijo.2009.252","DOI":"10.1038\/ijo.2009.252"},{"key":"2026051108205517897_j_acph-2021-0019_ref_039_w2aab3b7c17b1b6b1ab1ac39Aa","doi-asserted-by":"crossref","unstructured":"39. D. E. Smith, M. D. Marcus and K. L. Eldredge, Binge eating syndromes: A review of assessment and treatment with an emphasis on clinical application, Behav. Ther.25 (1994) 635\u2013665; https:\/\/doi.org\/10.1016\/S0005-7894(05)80202-310.1016\/S0005-7894(05)80202-3","DOI":"10.1016\/S0005-7894(05)80202-3"},{"key":"2026051108205517897_j_acph-2021-0019_ref_040_w2aab3b7c17b1b6b1ab1ac40Aa","doi-asserted-by":"crossref","unstructured":"40. S. R. Salpeter, N. S. Buckley, J. A. Kahn and E. E. Salpeter, Meta-analysis: metformin treatment in persons at risk for diabetes mellitus, Am. J. Med.121 (2008) 149\u2013157; https:\/\/doi.org\/10.1016\/j.amjmed.2007.09.01610.1016\/j.amjmed.2007.09.01618261504","DOI":"10.1016\/j.amjmed.2007.09.016"}],"container-title":["Acta Pharmaceutica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/content.sciendo.com\/view\/journals\/acph\/71\/2\/article-p279.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/acph-2021-0019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:45:20Z","timestamp":1778489120000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/acph-2021-0019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,4]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,11,4]]},"published-print":{"date-parts":[[2021,6,1]]}},"alternative-id":["10.2478\/acph-2021-0019"],"URL":"https:\/\/doi.org\/10.2478\/acph-2021-0019","relation":{},"ISSN":["1846-9558"],"issn-type":[{"value":"1846-9558","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,4]]}}}